类风湿关节炎有癌症史患者启用靶向治疗后的癌症风险:系统评价与荟萃分析
该系统评价纳入24项观察性研究,其中12项针对类风湿关节炎(RA)患者进行荟萃分析,比较有癌症史者接受或不接受bDMARDs后新发或复发癌症的风险。结果显示总体肿瘤风险无显著增加(RR 1.09,95%CI 0.92-1.32),但皮肤癌复发风险轻度升高(RR 1.32,95%CI 1.02-1.72)。
要点
- 有癌症史的RA患者使用bDMARDs总体肿瘤风险未显著增加(RR 1.09,95%CI 0.92-1.32)。
- 皮肤癌复发风险轻度升高(RR 1.32,95%CI 1.02-1.72,P=0.04)。
- TNF抑制剂和利妥昔单抗的肿瘤风险均无显著增加。
核心结论
- 除皮肤癌(包括黑色素瘤)外,有癌症史的RA患者启用bDMARDs后复发或新发癌症风险与未使用bDMARDs者相比未增加。
研究设计与样本
- 系统检索截至2019年6月的文献,纳入24项观察性研究,其中12项RA患者研究进入荟萃分析。
- 研究对象为有癌症史的RA、中轴型脊柱关节炎(SpA)或银屑病关节炎(PsA)成人患者,暴露为bDMARDs或tsDMARDs。
主要发现
- RA有癌症史者使用任何bDMARDs的总体肿瘤风险RR为1.09(95%CI 0.92-1.32;P=0.31,I2=8%)。
- 使用TNF抑制剂者肿瘤风险RR为1.11(95%CI 0.85-1.46;P=0.45,I2=48%)。
- 使用利妥昔单抗者肿瘤风险RR为0.79(95%CI 0.41-1.53;P=0.49,I2=0%)。
- 皮肤癌复发风险RR为1.32(95%CI 1.02-1.72;P=0.04,I2=0%)。
- 乳腺肿瘤风险RR为1.21(95%CI 0.84-1.72;P=0.31,I2=0%)。
临床怎么用
- 对有癌症史的RA患者,启用bDMARDs前应个体化评估,总体肿瘤风险未显著增加。
- 需特别关注皮肤癌(包括黑色素瘤)的复发风险,加强皮肤监测。
局限性
- 纳入研究均为观察性研究,可能存在混杂偏倚。
- 部分分析异质性较高(如TNF抑制剂I2=48%)。
- 仅12项RA研究进入荟萃分析,SpA和PsA数据未汇总。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the risk of recurrent or new malignancy with exposure to targeted disease-modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis (RA), axial spondyloarthritis (SpA), or psoriatic arthritis (PsA) and a history of cancer. METHODS: We performed a systematic search of the literature for articles published up to June 2019 that investigated adults with RA, axial SpA, or PsA who had a history of cancer and received biologic or targeted synthetic DMARDs (bDMARDs or tsDMARDs). We compared the risk of relapse or occurrence of new cancer between patients with and without bDMARDs. Rate ratios (RRs) with 95% confidence intervals (95% CIs) were estimated. The heterogeneity of the studies was evaluated by the Cochran Q test and the I2 statistic. RESULTS: We included 24 observational studies of chronic inflammatory arthritis; of those, 12 were included in the meta-analysis of RA patients receiving bDMARDs. As compared with RA patients with a history of cancer and not receiving bDMARDs, for those receiving any bDMARD, the overall RR for risk of neoplasia was 1.09 (95% CI 0.92-1.32; P = 0.31, I2 = 8%); with tumor necrosis factor inhibitors, it was 1.11 (95% CI 0.85-1.46; P = 0.45, I2 = 48%); and with rituximab, it was 0.79 (95% CI 0.41-1.53; P = 0.49, I2 = 0%). The RR for risk of recurrence for skin cancer was 1.32 (95% CI 1.02-1.72; P = 0.04, I2 = 0%) and for breast neoplasia 1.21 (95% CI 0.84-1.72; P = 0.31, I2 = 0%). CONCLUSION: Apart from skin cancers including melanoma, the risk of recurrent or new cancer is not increased with the initiation of bDMARDs for RA as compared with no bDMARDs.
引用
- Wetzman A, Lukas C, Gaujoux-Viala C, et al. Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis. Arthritis Care Res (Hoboken). 2022. PMID: 34549898. doi:10.1002/acr.24784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。